Dishman Carbogen Amcis Limited has allotted 1,500 Senior, Secured, Rated, Listed, Redeemable, Transferable, Taxable Non-Convertible Debentures (NCDs) aggregating ₹15 crore through a private placement. The allotment was approved by the Management Committee of the Board of Directors on September 28, 2026.

The debentures were issued at par for cash, with a face value of ₹1 lakh each. This issuance is part of a broader board-approved plan to raise up to ₹150 crore via NCDs, as outlined in earlier disclosures from March 2026. The securities are listed and rated, offering investors a secured debt instrument with a fixed maturity profile.

Key Allotment Details

The following table summarizes the specific terms of the allotment:

Regulatory Compliance and Timeline

The allotment was executed in compliance with Regulations 30, 51, and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Management Committee meeting commenced at 11:40 am and concluded at 12:10 pm on the date of allotment.

The issue terms were governed by the General Information Document dated December 30, 2025, and the Key Information Document dated September 24, 2026. The company had previously intimated the stock exchanges regarding the Board's approval of the NCD issue framework in March 2026.

What the Numbers Show

The current allotment of ₹15 crore represents 10% of the total ₹150 crore borrowing limit approved by the Board in March 2026. This indicates a phased approach to debt raising, where the company is tapping into its approved capital structure incrementally rather than executing the full quantum at once. With a tenor of approximately 18 months (September 2026 to March 2028), this tranche adds medium-term secured liabilities to the balance sheet, likely aligned with near-term working capital or capital expenditure requirements.

Dishman Carbogen Amcis announced that its wholly owned subsidiary, Carbogen Amcis AG, successfully completed its first US Food and Drug Administration inspection at its manufacturing site in Vionnaz, Switzerland.

The inspection concluded on September 11, 2026, with no observations raised by the regulator. The facility did not receive a Form 483 notice, which is typically issued for significant violations or deficiencies found during such audits.

Regulatory Compliance

The company disclosed the outcome pursuant to Regulations 30 and 51 of the SEBI (LODR) Regulations, 2015. The successful clearance underscores the subsidiary’s adherence to strict quality parameters required for the US market.

Dishman Carbogen Amcis stated that this result reflects the company’s strong focus on quality across its global operations. All manufacturing sites worldwide remain approved by major regulatory agencies.

What the Numbers Show

The absence of a Form 483 is a critical operational indicator. In pharmaceutical manufacturing, receiving no observations during a first-time FDA inspection suggests robust process validation and quality control systems are already in place, reducing the risk of future regulatory holds or export bans for products manufactured at the Vionnaz facility.